AEterna Zentaris Inc. Stock News

- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million   - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency– Safety and efficacy study AE

CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeuti

CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut

CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev

CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeu

CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializin

Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its pre

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a publi

Aeterna Zentaris Inc. (AEZS) (AEZS.TO) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entere